SG11201508453YA - Pharmaceutical composition and uses thereof - Google Patents
Pharmaceutical composition and uses thereofInfo
- Publication number
- SG11201508453YA SG11201508453YA SG11201508453YA SG11201508453YA SG11201508453YA SG 11201508453Y A SG11201508453Y A SG 11201508453YA SG 11201508453Y A SG11201508453Y A SG 11201508453YA SG 11201508453Y A SG11201508453Y A SG 11201508453YA SG 11201508453Y A SG11201508453Y A SG 11201508453YA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819709P | 2013-05-06 | 2013-05-06 | |
| PCT/US2014/036810 WO2014182620A1 (en) | 2013-05-06 | 2014-05-05 | Pharmaceutical composition and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201508453YA true SG11201508453YA (en) | 2015-11-27 |
Family
ID=51867665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201508453YA SG11201508453YA (en) | 2013-05-06 | 2014-05-05 | Pharmaceutical composition and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20160067238A1 (en) |
| EP (1) | EP2994197B1 (en) |
| JP (2) | JP6208332B2 (en) |
| KR (2) | KR102027663B1 (en) |
| CN (1) | CN105555363B (en) |
| CA (2) | CA2911298C (en) |
| ES (1) | ES2871116T3 (en) |
| HK (1) | HK1219691A1 (en) |
| SG (1) | SG11201508453YA (en) |
| TW (2) | TWI617306B (en) |
| WO (1) | WO2014182620A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
| CA3063228C (en) | 2017-05-11 | 2022-06-28 | Nevakar Inc. | Atropine pharmaceutical compositions |
| WO2019018749A1 (en) | 2017-07-20 | 2019-01-24 | Alan Laboratories, Inc. | Composition and methods for the treatment of myopia |
| CA3087969A1 (en) | 2018-01-17 | 2019-07-25 | Eyenovia, Inc. | Methods and devices for delivering atropine to the eye as a micro-dose stream of droplets |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01226313A (en) * | 1988-03-07 | 1989-09-11 | Toyota Motor Corp | Preparation of resin molded item |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| KR920002149A (en) | 1990-07-03 | 1992-02-28 | 안드레아 엘. 콜비 | Pharmaceutical compositions for alleviating the symptoms of gastrointestinal disorders caused by nonsteroidal anti-inflammatory drugs and methods for alleviating the same |
| JP2000026313A (en) * | 1998-05-06 | 2000-01-25 | Hokuriku Seiyaku Co Ltd | Suppressant for enterokinesis |
| SE0002211D0 (en) * | 2000-06-13 | 2000-06-13 | Synphora Ab | Methods and compositions for prevention of myopia |
| ITMI20010733A1 (en) | 2001-04-05 | 2002-10-05 | Recordati Chem Pharm | USE OF ISOENZIN COX-2 INHIBITORS FOR THE TREATMENT OF URINARY INCONTINENCE |
| CA2866848C (en) * | 2002-07-30 | 2017-01-03 | Omeros Corporation | Ophthalmologic irrigation solutions and method |
| KR20050085563A (en) | 2002-12-13 | 2005-08-29 | 워너-램버트 캄파니 엘엘씨 | Alpha-2-delta ligand to treat lower urinary tract symptoms |
| CA2582374A1 (en) | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
| CN1302812C (en) | 2004-11-30 | 2007-03-07 | 中国海洋大学 | Transmission system of medicine containing trehalose and hyaluronic acid for eye part and its preparation method |
| US20070254914A1 (en) * | 2006-05-01 | 2007-11-01 | Non-Profit Organization Chang Gung Memorial Hospital | Low-concentration atropine solution for preventing myopia progression and preparing method thereof |
| EP2203051A4 (en) | 2007-09-25 | 2011-09-07 | Abbott Lab | Octahydropentalene compounds as chemokine receptor antagonists |
| BRPI0908502A2 (en) * | 2008-02-21 | 2017-05-23 | Ista Pharmaceuticals | ophthalmic aines as adjuvants |
| US9046699B2 (en) | 2012-03-13 | 2015-06-02 | Johnson & Johnson Vision Care, Inc. | Dynamic fluid zones in contact lenses |
| EP2844227B1 (en) * | 2012-05-03 | 2020-11-18 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| MY186510A (en) | 2012-05-21 | 2021-07-23 | Univ Nat Taiwan | Methods for drug screen using zebrafish model and the compounds screened therefrom |
| US9827250B2 (en) * | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
-
2014
- 2014-05-05 KR KR1020177021970A patent/KR102027663B1/en active IP Right Grant
- 2014-05-05 CA CA2911298A patent/CA2911298C/en active Active
- 2014-05-05 WO PCT/US2014/036810 patent/WO2014182620A1/en active Application Filing
- 2014-05-05 US US14/787,051 patent/US20160067238A1/en not_active Abandoned
- 2014-05-05 EP EP14794664.4A patent/EP2994197B1/en active Active
- 2014-05-05 CA CA3050457A patent/CA3050457C/en active Active
- 2014-05-05 ES ES14794664T patent/ES2871116T3/en active Active
- 2014-05-05 KR KR1020157031483A patent/KR20160004288A/en active Application Filing
- 2014-05-05 SG SG11201508453YA patent/SG11201508453YA/en unknown
- 2014-05-05 JP JP2016512991A patent/JP6208332B2/en active Active
- 2014-05-05 CN CN201480024605.2A patent/CN105555363B/en active Active
- 2014-05-06 TW TW105126589A patent/TWI617306B/en active
- 2014-05-06 TW TW103116020A patent/TWI562776B/en active
-
2016
- 2016-07-04 HK HK16107697.3A patent/HK1219691A1/en unknown
-
2017
- 2017-08-03 JP JP2017150880A patent/JP6450814B2/en active Active
-
2018
- 2018-04-20 US US15/958,440 patent/US10548887B2/en active Active
-
2019
- 2019-12-03 US US16/701,707 patent/US10888556B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160004288A (en) | 2016-01-12 |
| US20160067238A1 (en) | 2016-03-10 |
| CN105555363A (en) | 2016-05-04 |
| US10548887B2 (en) | 2020-02-04 |
| JP2016518410A (en) | 2016-06-23 |
| EP2994197A1 (en) | 2016-03-16 |
| TWI617306B (en) | 2018-03-11 |
| ES2871116T3 (en) | 2021-10-28 |
| JP6450814B2 (en) | 2019-01-09 |
| WO2014182620A1 (en) | 2014-11-13 |
| JP2018008991A (en) | 2018-01-18 |
| CA3050457A1 (en) | 2014-11-13 |
| JP6208332B2 (en) | 2017-10-04 |
| KR20170094552A (en) | 2017-08-18 |
| EP2994197A4 (en) | 2016-12-28 |
| US10888556B2 (en) | 2021-01-12 |
| EP2994197B1 (en) | 2021-04-28 |
| CA2911298C (en) | 2019-09-17 |
| KR102027663B1 (en) | 2019-10-01 |
| US20200113890A1 (en) | 2020-04-16 |
| CA2911298A1 (en) | 2014-11-13 |
| CN105555363B (en) | 2019-03-12 |
| TW201446245A (en) | 2014-12-16 |
| HK1219691A1 (en) | 2017-04-13 |
| US20180311227A1 (en) | 2018-11-01 |
| TW201641105A (en) | 2016-12-01 |
| TWI562776B (en) | 2016-12-21 |
| CA3050457C (en) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1223975A1 (en) | Nanobubble-containing composition and use thereof | |
| ZA201602510B (en) | Strigolactone formulations and uses thereof | |
| RS59756B1 (en) | Combined pharmaceutical composition | |
| IL240290A0 (en) | Pyridazinone-amides derivatives and pharmaceutical compositions containing them | |
| GB201317286D0 (en) | Composition and Use | |
| HK1220920A1 (en) | Therapeutic compositions and uses thereof | |
| HK1222563A1 (en) | Pharmaceutical composition, preparation and uses thereof | |
| GB201321693D0 (en) | Composition and uses thereof | |
| PT3058936T (en) | Peptide composition and uses thereof | |
| IL276126B (en) | Compositions comprising l-4-chlorokynurenine and uses thereof | |
| EP2990038A4 (en) | Solid pharmaceutical composition | |
| EP2995308A4 (en) | Antihypoxic pharmaceutical composition and application thereof | |
| EP3007720A4 (en) | Compositions comprising gc- macrophage activating factor and uses thereof | |
| HK1219691A1 (en) | Pharmaceutical composition and uses thereof | |
| SG11201601477VA (en) | Pharmaceutical composition | |
| GB201301979D0 (en) | New composition and use thereof | |
| IL240177A0 (en) | Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals | |
| HUP1300496A2 (en) | Stable pharmaceutical composition | |
| GB201307082D0 (en) | Pharmaceutical composition comprising 15-HETrE and methods of using the same | |
| HK1220143A1 (en) | Pharmaceutical composition | |
| ZA201601880B (en) | Hetero-transglycosylase and uses thereof | |
| IL284405A (en) | Pharmaceutical composition, preparation and uses thereof | |
| GB201301022D0 (en) | Composition and uses thereof | |
| GB201322467D0 (en) | Composition and use | |
| GB201308242D0 (en) | Compositions and uses thereof |